

LIST OF TABLES

Table 2-1 Chemotherapeutics used for NSCLC	23
Table 2-2 Approaches used in reversal of resistance in cancer	26
Table 2-3 Types of HNCs	32
Table 2-4 HNCs Reported in Literature.....	34
Table 2-5 HNCs excipients profile	40
Table 3-1 List of materials used with their sources	47
Table 3-2 List of Equipment Used.....	47
Table 3-3 NP-HPLC Process Parameters	50
Table 3-4 Process Parameters	51
Table 3-5 Calibration Plot of Cisplatin	56
Table 3-6 Accuracy of method with OPDA	57
Table 3-7 Intraday and Interday precision of Cisplatin with OPDA (in DMF: Water Mixture 7:3 v/v, pH 6.2)	58
Table 3-8 LOD and LOQ of Cisplatin with OPDA	58
Table 3-9 Calibration curve of Cisplatin by NP-HPLC.....	58
Table 3-10 Calibration curve of Cisplatin in rat plasma by NP-HPLC	61
Table 3-11 Calibration curve of Cisplatin in Lung homogenate by NP-HPLC	62
Table 3-12 Calibration data for estimation of total phospholipid content	63
Table 3-13 Obtained concentration of siRNA at 260 nm	65
Table 3-14 Optimized parameters for gel electrophoresis	66
Table 3-15 Relative band densities at different siRNA concentrations	67
Table 4-1 List of materials used with their sources	70
Table 4-2 List of Equipment Used.....	70
Table 4-3 Purity and concentration determination of siRNA using nanodrop	74
Table 4-4 Cisplatin caprylate complex formation at different molar ratio	76
Table 5-1 List of materials used with their sources	85
Table 5-2 List of Equipment Used.....	86
Table 5-3 Effect of process parameters for formation of films	95
Table 5-4 HNCs formulation Preliminary screening	97
Table 5-5 Selected variables for BBD	98

Table 5-6 Variables and levels selected for preliminary study.....	100
Table 5-7 Optimization of formulation parameter using BBD.....	100
Table 5-8 Summary of ANOVA results of different models (variable 1).....	106
Table 5-9 ANOVA results of Quadratic mixture model (variable 1).....	106
Table 5-10 Summary of ANOVA results for nanocarrier size.....	107
Table 5-11 Summary of ANOVA results of different models (variable 2)...	115
Table 5-12 ANOVA results of Quadratic mixture model (variable 2).....	115
Table 5-13 Summary of ANOVA results for Entrapment efficiency.....	116
Table 5-14 Variables for desirability plot and goals for response.....	124
Table 5-15 Optimized batch (R1) of the HNCs.....	124
Table 5-16 Evaluation of desirability batch.....	125
Table 5-17 Check point batch analysis.....	127
Table 5-18 Predicted responses for selected solution along with standard deviation.....	128
Table 5-19 Composition and Parameters for optimized batch (R1) Cisplatin caprylate loaded HNCs.....	128
Table 5-20 Residual solvent (Chloroform) Analysis.....	134
Table 6-1 List of Materials.....	139
Table 6-2 List of Equipments.....	140
Table 6-3 Selection of process parameters for preformed Cisplatin caprylate loaded siRNA-HNCs complexes.....	145
Table 6-4 Cisplatin loaded siRNA anchored HNCs characterization.....	147
Table 7-1 List of Materials.....	155
Table 7-2 List of Instruments.....	155
Table 7-3 Cell line treatment parameters for confocal microscopy and flow cytometry of HNCs based formulations.....	164
Table 7-4 Details of primers.....	173
Table 7-5 mRNA quantification – reaction parameters.....	174
Table 7-6 IC50 Values of Cisplatin caprylate loaded HNCs, Cisplatin caprylate loaded siRNA-HNCs and Cisplatin solution.....	182
Table 8-1 List of materials used with their sources.....	191
Table 8-2 List of Equipment Used.....	191
Table 8-3 Influence of Trehalose in different ratio.....	198

Table 8-4 Influence of Lactose in different Ratios	198
Table 8-5 Determination of Titer Value	199
Table 8-6 Determination of moisture content of lyophilized samples.....	200
Table 8-7 Characterization of aerodynamic behaviour using inhalac 230 as carrier	Error! Bookmark not defined.
Table 8-8 Characterization of aerodynamic behaviour using Respitose SV003 as carrier.....	Error! Bookmark not defined.
Table 8-9 Peak list of the pure drug.....	205
Table 8-10 Peak list of the DPI.....	205
Table 8-11 Assay of % complexation of siRNA with HNCs after Lyophilization and powder processing	207
Table 9-1 Concentration of drug in Lung homogenate and BAL after intratracheal instillation	215
Table 9-2 Pulmonary and IV Pharmacokinetic Parameters	217
Table 9-3 MTD Study: Dosing Protocol.....	220
Table 9-4 Results of MTD study	220
Table 10-1 Stability Testing Conditions for Drug Product Intended for Storage in Refrigerator as per ICH Guideline Q1A(R2).....	225
Table 10-2 Results of stability study (mean± SD).....	226